{"id":49388,"date":"2023-05-02T10:43:34","date_gmt":"2023-05-02T05:13:34","guid":{"rendered":"http:\/\/finservwealth.com\/sun-pharma-says-us-fda-puts-partial-clinical-hold-on-its-dermatological-drug\/"},"modified":"2023-05-02T10:43:34","modified_gmt":"2023-05-02T05:13:34","slug":"sun-pharma-says-us-fda-puts-partial-clinical-hold-on-its-dermatological-drug","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/sun-pharma-says-us-fda-puts-partial-clinical-hold-on-its-dermatological-drug\/","title":{"rendered":"Sun Pharma says US FDA puts partial clinical hold on its dermatological drug"},"content":{"rendered":"<p> Indian drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday the U.S. Food and Drug Administration (FDA) had put a partial clinical hold on its application for an experimental dermatological drug due to the potential of thrombotic events.<\/p><div id=\"finse-1215487021\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/business\/sun-pharma-says-us-fda-puts-partial-clinical-holdits-dermatological-drug_16979891.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Indian drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday the U.S. Food and Drug Administration (FDA) had put a partial clinical hold on its application for an experimental dermatological drug due to the potential of thrombotic events. Indian drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday the U.S. Food and Drug Administration (FDA) had put a partial clinical hold on its application for an experimental dermatological drug due to the potential of thrombotic events.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/business\/sun-pharma-says-us-fda-puts-partial-clinical-holdits-dermatological-drug_16979891.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Indian drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday the U.S. Food and Drug Administration (FDA) had put a partial clinical hold on its application for an experimental dermatological drug due to the potential of thrombotic events.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/business\/sun-pharma-says-us-fda-puts-partial-clinical-holdits-dermatological-drug_16979891.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Indian drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday the U.S. Food and Drug Administration (FDA) had put a partial clinical hold on its application for an experimental dermatological drug due to the potential of thrombotic events. Indian drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday the U.S. Food and Drug Administration (FDA) had put a partial clinical hold on its application for an experimental dermatological drug due to the potential of thrombotic events.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/business\/sun-pharma-says-us-fda-puts-partial-clinical-holdits-dermatological-drug_16979891.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Indian drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday the U.S. Food and Drug Administration (FDA) had put a partial clinical hold on its application for an experimental dermatological drug due to the potential of thrombotic events.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-49388","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2020\/200x200\/S\/SUN-PHARMACEUTICALS-INDUSTRIES_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/49388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=49388"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/49388\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=49388"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=49388"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=49388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}